JP2014506890A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506890A5
JP2014506890A5 JP2013554520A JP2013554520A JP2014506890A5 JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5 JP 2013554520 A JP2013554520 A JP 2013554520A JP 2013554520 A JP2013554520 A JP 2013554520A JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5
Authority
JP
Japan
Prior art keywords
hydroxy
use according
methylbutyrate
disease
mechirubuchira
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013554520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506890A (ja
JP6034309B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024817 external-priority patent/WO2012112419A1/en
Publication of JP2014506890A publication Critical patent/JP2014506890A/ja
Publication of JP2014506890A5 publication Critical patent/JP2014506890A5/ja
Application granted granted Critical
Publication of JP6034309B2 publication Critical patent/JP6034309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013554520A 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 Expired - Fee Related JP6034309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
US61/443,762 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016209276A Division JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Publications (3)

Publication Number Publication Date
JP2014506890A JP2014506890A (ja) 2014-03-20
JP2014506890A5 true JP2014506890A5 (https=) 2015-03-26
JP6034309B2 JP6034309B2 (ja) 2016-11-30

Family

ID=45757211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013554520A Expired - Fee Related JP6034309B2 (ja) 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Country Status (12)

Country Link
US (1) US9326956B2 (https=)
EP (1) EP2675298A1 (https=)
JP (2) JP6034309B2 (https=)
CN (1) CN103347406B (https=)
AR (1) AR085297A1 (https=)
BR (1) BR112013020643A2 (https=)
CA (1) CA2825734C (https=)
MX (1) MX348708B (https=)
PH (1) PH12013501671A1 (https=)
SG (1) SG192813A1 (https=)
TW (1) TWI565420B (https=)
WO (1) WO2012112419A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
JP5892948B2 (ja) 2010-01-29 2016-03-23 アボット・ラボラトリーズAbbott Laboratories カルシウムhmbを含む栄養エマルジョン
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣hmb及可溶性蛋白質之實質上透明營養液
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
WO2014120730A2 (en) * 2013-01-29 2014-08-07 Otc Nutrition Llc Micronutrient fortification delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
MX2015013179A (es) * 2013-03-15 2016-04-20 Abbott Lab Formula infantil con bajo contenido calorico que contiene acido beta-hidroxi-beta-metilbutirico.
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2806684T3 (es) * 2015-09-16 2021-02-18 Abbott Lab Composición nutricional líquida, de larga duración y reducida en grasas
CN108770334B (zh) * 2015-11-10 2022-10-28 代谢科技有限公司 β-羟基-β-甲基丁酸系化合物(HMB)的组合物和使用其作为动物饲料添加剂的方法
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 HMBCa含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) * 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
CA2746420C (en) 2008-12-09 2019-11-12 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
SG191315A1 (en) 2010-12-22 2013-07-31 Abbott Lab Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
CA2821312A1 (en) 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
CN104411305A (zh) 2012-03-19 2015-03-11 雅培制药有限公司 用于改善葡萄糖耐受的β-羟基-β-甲基丁酸
CA2885211A1 (en) 2012-09-17 2014-03-20 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid-containing compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2014506890A5 (https=)
Stoodley et al. The cerebellum and dyslexia.
EP4272828A3 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
CL2019000129A1 (es) Compuestos diazaheterobicíclicos sustituidos y su uso.
BR112015014800A2 (pt) derivados da exendina-4 funcionalizada
SG10201903475TA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
UY37013A (es) 2-fenil-3-(piperazinometil)imidazopiridinas sustituidas y su uso
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
JP2014514361A5 (https=)
JP2014507474A5 (https=)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
BR112013005226A2 (pt) "n-fenetiltriazolonaacetamidas substituídas e o seu uso".
Isaac Culture‐bound syndromes in mental health: A discussion paper.
WO2014203188A3 (en) Assay for complement factor i (cfi) bioactivity
Messinger-Rapport et al. Clinical update on nursing home medicine: 2011
Paxton Time for Dementia
PL3085383T3 (pl) Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona
Saxena et al. Assessment of neuropro-tective potential of Tualang honey in Alzheimer model of rat
CN105685302A (zh) 一种药花茶
Johansson et al. " Fathers’ everyday experiences of having an adult child who suffers from long-term mental illness": Erratum.
CN105287960A (zh) 一种补肾益气的药物
Administration et al. Exclusion of orphan drugs for certain covered entities under 340B Program. Final rule
Shim et al. ERRATUM: Acknowledgments Correction. Iodinated contrast media-induced fixed drug eruption